Tamas Treuer

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. pmc Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study
    Istvan Bitter
    Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
    World J Biol Psychiatry 11:894-903. 2010
  2. pmc A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability
    Tamas Treuer
    Neuroscience Research, Eli Lilly and Company, Budapest, Hungary
    J Child Adolesc Psychopharmacol 23:179-93. 2013
  3. ncbi request reprint Parasitosis, dopaminergic modulation and metabolic disturbances in schizophrenia: evolution of a hypothesis
    Tamas Treuer
    Neuroscience Research, Area Medical Center Vienna, Eli Lilly Regional GmbH, Venna, Austria
    Neuro Endocrinol Lett 28:535-40. 2007
  4. ncbi request reprint Acute phase results from STORM, a multicountry observational study of bipolar disorder treatment and outcomes
    Tamas Treuer
    Area Medical Center Vienna, Neuroscience Research, Eli Lilly Regional GesmbH, Koelblgasse 8 10, 1030 Wien, Austria
    Psychiatr Danub 19:282-95. 2007
  5. doi request reprint Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study
    Tamas Treuer
    Neuroscience Research, Lilly Hungaria Kft, Budapest, Hungary
    World J Biol Psychiatry 10:729-40. 2009
  6. ncbi request reprint Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study
    Istvan Bitter
    Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
    Eur Neuropsychopharmacol 18:170-80. 2008
  7. ncbi request reprint Weight Gain Risk Factor assessment checklist: overview and recommendation for use
    Tamas Treuer
    Neuroscience Research, Lilly Hungaria Kft, Hungary
    Neuro Endocrinol Lett 32:199-205. 2011
  8. ncbi request reprint Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa
    Martin Dossenbach
    Eli Lilly Austria Medical Department, Eli Lilly Regional GmbH, Vienna, Austria
    J Clin Psychopharmacol 27:329-37. 2007
  9. pmc The potential role of appetite in predicting weight changes during treatment with olanzapine
    Michael Case
    Lilly USA, LLC, Indianapolis, IN, USA
    BMC Psychiatry 10:72. 2010
  10. doi request reprint Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain
    Jamie Karagianis
    Clinical Research, Eli Lilly Canada Inc, Toronto, Ontario, Canada
    Hum Psychopharmacol 23:275-81. 2008

Detail Information

Publications12

  1. pmc Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study
    Istvan Bitter
    Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
    World J Biol Psychiatry 11:894-903. 2010
    ..The aim of this study was to compare patients' preference for olanzapine orodispersible tablet (ODT) with oral conventional tablet (OCT)...
  2. pmc A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability
    Tamas Treuer
    Neuroscience Research, Eli Lilly and Company, Budapest, Hungary
    J Child Adolesc Psychopharmacol 23:179-93. 2013
    ....
  3. ncbi request reprint Parasitosis, dopaminergic modulation and metabolic disturbances in schizophrenia: evolution of a hypothesis
    Tamas Treuer
    Neuroscience Research, Area Medical Center Vienna, Eli Lilly Regional GmbH, Venna, Austria
    Neuro Endocrinol Lett 28:535-40. 2007
    ..We believe this model may well open up new avenues of research in the discovery of drugs to counteract schizophrenia...
  4. ncbi request reprint Acute phase results from STORM, a multicountry observational study of bipolar disorder treatment and outcomes
    Tamas Treuer
    Area Medical Center Vienna, Neuroscience Research, Eli Lilly Regional GesmbH, Koelblgasse 8 10, 1030 Wien, Austria
    Psychiatr Danub 19:282-95. 2007
    ..Particular emphasis was placed on investigating outcomes associated with treatment regimens including and excluding the atypical antipsychotic olanzapine...
  5. doi request reprint Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study
    Tamas Treuer
    Neuroscience Research, Lilly Hungaria Kft, Budapest, Hungary
    World J Biol Psychiatry 10:729-40. 2009
    ..These results indicate that the influence of environmental, eating- and lifestyle-related factors should be considered when assessing weight gain during olanzapine therapy...
  6. ncbi request reprint Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study
    Istvan Bitter
    Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
    Eur Neuropsychopharmacol 18:170-80. 2008
    ..001). However, treatment modification due to patient request was significantly greater for olanzapine-treated patients, compared to risperidone-, quetiapine- or haloperidol-treated patients (p<or=.001)...
  7. ncbi request reprint Weight Gain Risk Factor assessment checklist: overview and recommendation for use
    Tamas Treuer
    Neuroscience Research, Lilly Hungaria Kft, Hungary
    Neuro Endocrinol Lett 32:199-205. 2011
    ..Patients with mental illness are at risk for weight gain. Evidence-based risk assessment checklists have the potential to identify patients at risk early in treatment and improve patient outcomes...
  8. ncbi request reprint Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa
    Martin Dossenbach
    Eli Lilly Austria Medical Department, Eli Lilly Regional GmbH, Vienna, Austria
    J Clin Psychopharmacol 27:329-37. 2007
    ..09 +/- 1.11; chlorpromazine, 0.72 +/- 2.04; P = 0.042). This analysis suggests that, compared with chlorpromazine, olanzapine may be more efficacious and have a more favorable tolerability profile in treating patients with schizophrenia...
  9. pmc The potential role of appetite in predicting weight changes during treatment with olanzapine
    Michael Case
    Lilly USA, LLC, Indianapolis, IN, USA
    BMC Psychiatry 10:72. 2010
    ..Clinically significant weight gain has been reported during treatment with atypical antipsychotics. It has been suggested that weight changes in patients treated with olanzapine may be associated with increased appetite...
  10. doi request reprint Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain
    Jamie Karagianis
    Clinical Research, Eli Lilly Canada Inc, Toronto, Ontario, Canada
    Hum Psychopharmacol 23:275-81. 2008
    ..The data are still preliminary and mechanisms of action are not well understood. Randomized controlled trials are needed to further evaluate change in weight during treatment with orally disintegrating olanzapine...
  11. ncbi request reprint Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools
    Jamie Karagianis
    Eli Lilly Canada Inc, Toronto, Ontario, Canada
    Curr Med Res Opin 23:2551-7. 2007
    ....
  12. ncbi request reprint Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study
    Martin Dossenbach
    Eli Lilly and Company, Ges m b H, K├Âlblgasse 8 10, 1030 Vienna, Austria
    Eur Psychiatry 21:251-8. 2006
    ..This report will compare the effects of selected atypical and typical antipsychotics on sexual function in a large, international population of outpatients with schizophrenia who were treated over 1 year...